3 Big Biotechs Hold Growth Potential in Second Half of 2019

The biotech sector has always persisted to be riskier than the more stable large cap pharmaceuticals industry or the overall medical sector as investors are mostly banking on the product pipelines with a very few companies having approved drugs in their portfolio. An unfavorable outcome from a key trial on a promising candidate can spell doomsday for that particular biotech player. Nevertheless, things are now looking up for the sector, which in the past reaped solid returns for the risk-taking investor. Notably, the sector has performed better than the large cap pharmaceuticals industry so far.